| Date | Title | Description |
| 10.07.2026 | XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease | Financing round led by new investor Jeito Capital with participation from existing investors
Proceeds will support two double-blind Phase 2 clinical trials of lead candidate, XC001, which has demonstrated transformative potential for treatm... |
| 06.07.2026 | ReproNovo announces first participant dosed in EU Phase 2 Trial of RPN-002 for Embryo Implantation | - RPN-002 is an orally administered oxytocin receptor antagonist aiming to improve IVF/ICSI success rates
- The NORDIC study marks an important step in advancing ReproNovo’s global Phase 2 pipeline acrossfertility and women’s health, with f... |
| 22.06.2026 | Bionyra Pharma Raises $165 Million Series A To Advance Biologics For Inflammatory Diseases | Bionyra Pharma announced its launch and an oversubscribed $165 million Series A financing round. The round was co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Heal... |
| 22.06.2026 | Bionyra Pharma Raises $165M in Series A Funding | Bionyra Pharma, a Paris, France- and Boston, MA-based clinical-stage biopharmaceutical company developing new biologics for immune-mediated inflammatory diseases, raised $165M in Series A funding.
The round was led by Jeito Capital and Sofi... |
| 05.05.2026 | Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent | Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, a... |
| 14.04.2026 | Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology | Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, is leading an oversubscribed $75 million (€ 65 million2) Series C financing round in Adcendo ApS (“Adcendo”), a biopharma company focused on t... |
| 08.04.2026 | Jeito hails $1.2B as 'largest raise ever' for independent biopharma-focused European fund | Jeito Capital has hailed the $1.2 billion it has secured as the “largest raise ever achieved” by an independent biopharma-focused European fund.
The Paris, France-based private equity fund raised over €1 billion for its second fund, dubbed ... |
| 08.04.2026 | Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients | Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, today announces the final closing of its second fund Jeito II, exceeding its target at $1.2 billion (above €1 billion)1,2, and marking a new major mil... |
| 22.05.2025 | ReproNovo's $65 Million Leap: A New Dawn for Reproductive Health | In a world where fertility rates are slipping like sand through fingers, ReproNovo emerges as a beacon of hope. This Swiss HealthTech startup, founded in 2021, has just secured $65 million in Series A financing. The funding round, led by Je... |
| 21.05.2025 | ReproNovo raises USD65 million to advance Phase II clinical trials |
ReproNovo, founded in 2021, is developing novel approaches to address critical gaps in reproductive medicine and women’s health, including male and female infertility as well as uterine health. The company, led by a team with expertise in ... |
| 07.01.2025 | Jeito Capital's Bold Moves in Biopharma: A Strategic Investment Landscape | In the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm... |
| 07.01.2025 | French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics | Paris-based Jeito Capital, a PE fund focused on biopharma innovation, has furthered its position as a player in global healthcare investment with two major contributions to clinical-stage biotech companies Aviceda Therapeutics and XyloCor T... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA
Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| 12.11.2024 | Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors | Jeito Capital co-leads €164.5 million1 ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of
Anti-Claudin-1 (CLDN1) ADCs in solid tumors
Building on its co-lead investments in Alentis ... |
| 29.05.2024 | Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion | - |
| 07.09.2023 |
Corteria Pharmaceuticals Announces a €65M Financing to Advance Transformational Medicines in Cardiovascular Diseases | Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M) Series A co-led by US ... |
| 13.04.2023 | Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis | - |
| 13.04.2023 | Alentis Therapeutics closes USD 105 million Series C round | |
| 07.03.2023 | Noema Pharma raises CHF103 million | |
| 13.04.2022 | CDR-Life Closes $76 million Series A Funding | |
| 17.03.2022 | Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals | Brussels, Belgium, 16 March 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capit... |
| 29.11.2021 | Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
| 29.11.2021 | Syncona : Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
| 29.11.2021 | Jeito Capital Co-Leads $156 Million Oversubscribed Series B Financing In Quell Therapeutics | Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the imm... |
| 04.10.2021 | Finanțări pentru startup-uri medicale europene prin fonduri de investiții de 1,7 miliarde Euro | Startup-urile și firme mai dezvoltate, care inovează în medicină și alte științe ale vieții, au la dispoziție finanțări totale 1,7 miliarde de euro, prin 8 fonduri de investiții europene, susținute de UE și de mari companii, precum Google.
... |
| 21.09.2021 | Jeito Capital raises €534M for maiden fund | Jeito Capital, a Paris-based private equity firm focused on investments in the biotech and biopharma sectors, has reached a €534 million final close on its first fund, Jeito I. The fund aims to back businesses across the drug development va... |
| 20.09.2021 | Sanofi-backed Jeito Capital closes $630M fund to finance 12-15 European biopharmas | After gaining high-profile backing from Sanofi last November, French venture firm Jeito Capital has pulled together more partners to close its first fund at 534 million euros ($630 million).
That large pool of capital will go toward financi... |
| 20.09.2021 | Jeito Capital Closes Jeito I, At $534M | Jeito Capital, a Paris, France-based new, independent Private Equity firm dedicated to biotech and biopharma, closed its first fund, Jeito I, at €534m ($630m).
Jeito I received the support from global investors including the European Invest... |
| 16.06.2021 | USD67 million for Alentis Therapeutics | Alongside Morningside Venture Investments, Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital joined Alentis’ financing round.
&quo... |
| 16.06.2021 | USD67 million for Alentis Therapeutics | |
| 15.06.2021 | Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round | Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round
Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the fundAlentis is focused on the development of b... |
| 27.05.2021 | IP GROUP PLC
IP : Pulmocide Ltd - Raises $92 million in a Series C financing to fund registration program for PC945 | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million in an oversubscr... |
| 27.05.2021 | Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide | Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma company focused on the development of novel tr... |
| 27.05.2021 | IP : Pulmocide Ltd - Raises $92 million in a Series C financing to fund registration program for PC945 | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million in an oversubscr... |
| 13.11.2020 | Healthcare group Sanofi invests 50 million euros in Jeito Capital | PARIS: French healthcare giant Sanofi has invested 50 million euros (US$59 million) into Jeito Capital, an investment firm dedicated to biotech and biopharma, in a deal which Sanofi said would support French and European healthcare innovati... |
